Clinical trial · Observational
Effects of Radioactive Iodine on the Immune System in Thyroid Cancer
Effects on the Systemic Innate Immune System by Radioactive Iodine Treatment in Non-medullary Thyroid Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro stimulation of monocytes and in vitro ROS production by monocytes. These results are compared between patients treated in adjuvant setting and patients treated for persistent structural disease, and between pre- and post-treatment status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Carcinoma, Nonmedullary | Thyroid Gland Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood drawing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- I/adjuvant
- description
- 15 patients with thyroid carcinoma that are treated with radioacitive iodine in an adjuvant setting
- interventionNames
- Other: Blood drawing
- label
- II/structutral disease
- description
- 15 patients with thyroid carcinoma that are treated with radioactive iodine with the indication of persistent structural disease
- interventionNames
- Other: Blood drawing
Primary outcomes (3)
- measure
- Whole blood counts
- timeFrame
- 2 months
- description
- Whole blood counts with leukocyte subtypes (neutrophils, lymphocytes and monocytes) are compared before and after radioactive iodine treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed non-medullary thyroid cancer * Undergoing radioactive iodine treatment in an adjuvant setting or for persistent structural disease * Aged ≥ 18 years Exclusion Criteria: * Inflammatory or infectious comorbidities * Using medication interfering with the immune system * Pregnancy * A self-reported alcohol consumption of \>21 units per week * Other active malignancies, defined as malignancies not in complete remission for \<2 years * Previous systemic anti-cancer treatment such as chemotherapy, targeted therapy, radiotherapy or immunotherapy within 3 years before study procedures
References
Publications (0)
Data not yet available